ERLANGEN, Germany, Feb. 1, 2024/PRNewswire/ -- Siemens Healthcare today released its results report for the first quarter of the 2024 fiscal year ending December 31, 2023.

First quarter of fiscal year 2024 

• The equipment order shipment ratio was as high as 1.14
• Excluding the rapid COVID-19 antigen testing business, comparable revenue increased strongly by 7.0%; taking into account the rapid COVID-19 antigen testing business that was terminated in the fourth quarter of FY2023, the comparable revenue increased by 5.7%
• Comparable revenue from the video business increased by 5.3%; the adjusted profit margin before interest and tax was 19.1% due to the adverse effects of the short-term business portfolio
• Excluding the rapid COVID-19 antigen testing business, the comparable revenue of the laboratory diagnosis business increased by 1.6%; taking into account the discontinued rapid COVID-19 antigen testing business, the comparable revenue of the laboratory diagnosis business decreased by 4.0%; the adjusted profit margin before interest and tax was 5.1%
• Varian Corby's revenue increased significantly by 22.3%; adjusted profit margin before interest and tax was 15.9%
• Comparable revenue from the clinical treatment business increased by 5.0%; adjusted profit margin before interest and tax was 14.3%
• The overall adjusted profit margin before interest and tax reached 14.3%, higher than the same period last year
• Adjusted basic earnings per share of €0.49

FY2024 outlook

We confirm that Siemens Healthcare's comparable revenue for the 2024 fiscal year is expected to increase by 4.5% to 6.5%. Excluding the revenue from the rapid COVID-19 antigen testing business, the comparable revenue growth rate is expected to be 5.0% to 7.0%. Adjusted basic earnings per share are expected to reach between €2.10 and €2.30.

Meng Tianqi, CEO of Siemens Healthcare ((Bernd Montag): “We had a great start to the first quarter of FY2024 with extensive growth. The laboratory diagnosis business showed a positive development trend, and Varian showed even stronger performance. At the same time, we are more focused on the latest ambitious sustainable development goals.”

About Siemens Healthcare 

A world of innovation, for every life. Siemens Healthcare is a leading global provider of medical equipment, solutions and services. It operates in more than 180 countries and regions, and directly operates in more than 70 countries and regions. Siemens Healthcare consists of Siemens Healthcare AG (Frankfurt Stock Exchange: SHL) and its subsidiaries. As a leading medical technology company, Siemens Healthcare is committed to improving access to high-quality medical resources while overcoming fatal diseases that threaten human health. Siemens Healthcare's business covers fields such as medical imaging, in vitro diagnosis, cancer diagnosis and treatment, and minimally invasive treatment, and strengthens the strength of its various businesses through digital technology and artificial intelligence. As of fiscal year 2023 (September 30, 2023), Siemens Healthcare has around 71,000 employees worldwide and revenue of approximately €21.7 billion. For more information, please visit